Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef
/in HIV/AIDS, International Publications /von 2008-05-20 / Vaccine 2008 Jul;26(29-30):3735-41Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
/in Breast Cancer, International Publications /von 2008-05-15 / Cancer Res. 2008 May;68(10):3854-62Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency
/in International Publications, Malignant Melanoma /von 2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-9Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104Immunotherapy of pancreatic carcinoma
/in International Publications, Pancreatic Cancer /von 2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-5Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
/in International Publications, Malignant Melanoma /von 2008-05-01 / J. Immunother. 2008 May;31(4):402-12Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
/in International Publications, Malignant Melanoma /von 2008-05-01 / J. Immunother. 2008 May;31(4):345-58Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine
/in HIV/AIDS, International Publications /von 2008-05-01 / Eur. J. Immunol. 2008 May;38(5):1310-20
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution